2seventy bio Provides Update on KarMMa-9 Study and Previews Anticipated Strong Third Quarter Revenue Performance

Autor: 2seventy bio, Inc.
Zdroj: Business Wire (English). 09/25/2024.
Abstrakt: 2seventy bio, Inc. (Nasdaq: TSVT) today announced that the Company, in partnership with study sponsor Bristol Myers Squibb (BMS), will discontinue enrollment in its ongoing Phase 3 KarMMa-9 study evaluating Abecma® (idecabtagene vicleucel; ide-cel) with lenalidomide maintenance versus lenalidomide maintenance alone in patients with newly diagnosed multiple myeloma (NDMM) who have suboptimal response to autologous stem cell transplant. [ABSTRACT FROM PUBLISHER]
Databáze: Regional Business News
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje